BridgeBio LLC

89 articles with BridgeBio LLC

• 

  FDA Approves BridgeBio-QED Therapeutics' Targeted Liver Cancer Treatment

  6/1/2021

  The FDA approves Truseltiq for patients with previously-treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement.

• BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1

  6/1/2021

  BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, announced that the U.S. Food and Drug Administration granted Fast Track designation for encaleret for the treatment of autosomal dominant hypocalcemia.

• 

  LianBio is Driving Innovation in China with Next-Gen CEO Yizhe Wang

  5/24/2021

  Wang, who has played a key role in the development of more than 25 innovative medicines at Eli Lilly and GlaxoSmithKline, made him the ideal fit for the company’s next chapter.

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 14, 2021

  5/14/2021

  BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on May 4, 2021, the compensation committee of BridgeBio’s board of directors granted 27 new employees restricted stock units for an aggregate of 70,949 shares of the Company’s common stock.

• BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update

  5/6/2021

  – Received U.S. Food and Drug Administration (FDA) approval for NULIBRY™ (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency ( MoCD) Type A – Reported pr oof-of-concept data of encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) –

• BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases

  4/13/2021

  BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis), to advance research and the development of investigational medicines for patients with genetically driven conditions and cancers.

• BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers

  4/13/2021

  BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center today announced a collaboration to translate research in genetically driven diseases and cancers into potential treatments for patients.

• BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers

  4/13/2021

  BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance the development of investigational therapeutics for patients with genetically driven cancers.

• BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases

  4/13/2021

  BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Oregon Health & Science University (OHSU) in Portland, Oregon, to advance research and the development of investigational medicines for patients with genetically driven conditions.

• BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research

  4/13/2021

  BridgeBio Pharma, Inc. (NASDAQ: BBIO) and the Canadian Glycomics Network (GlycoNet), a pan-Canadian Network of Centres of Excellence, today announced a collaboration to translate scientific research in glycomics into potential treatments for patients with genetic diseases.

• BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions

  4/13/2021

  BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate research in genetically driven conditions into potential therapeutic applications for patients, with a focus on oncology and neurology.

• BridgeBio Pharma and Brown University Announce Partnership to Drive the Advancement of Academic Innovations in Genetically Driven Diseases into Potential Therapeutics for Patients

  4/13/2021

  BridgeBio Pharma, Inc. (NASDAQ: BBIO), and Brown University today announced a formal collaboration to advance research in genetically driven neurological disorders into potential life-changing medicines for patients.

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Apr 06, 2021

  4/6/2021

  BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on April 5, 2021, the compensation committee of BridgeBio’s board of directors granted 19 new employees restricted stock units for an aggregate of 32,691 shares of the Company’s common stock.

• BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting

  3/20/2021

  Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over 5 Days Demonstrates Proof-of-Concept

• BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

  2/28/2021

  Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high infant mortality rate; median overall survival age is about four years

• BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update

  2/25/2021

  – Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos’ product candidate, acoramidis, a potential best-in-class therapy for patients with amyloidosis cardiomyopathy (ATTR-CM)

• BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting

  2/24/2021

  BridgeBio Pharma, Inc. announced that early results from an ongoing Phase 2 proof-of-concept study of encaleret for the treatment of Autosomal Dominant Hypocalcemia Type 1 will be shared at the upcoming Endocrine Society’s 2021 Annual Meeting taking place virtually from March 20 - 23.

• BridgeBio Pharma, Inc. Announces Launch of Secondary Offering of Common Stock

  2/11/2021

  BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the launch of a secondary public offering of 3,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P. The selling stockholder has also granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock. All shares are being sold by KKR Genetic Disorder L.P.

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Feb 05, 2021

  2/5/2021

  BridgeBio Pharma, Inc., a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on February 1, 2021, the compensation committee of BridgeBio’s board of directors granted 11 new employees restricted stock units for an aggregate of 16,772 shares of the Company’s common stock.

• BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million Convertible Senior Notes

  1/26/2021

  BridgeBio Pharma, Inc. announced the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.